MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.isci.2026.115433

Медицинская библиотека · iScience · 2026

Intranasal replicating adenovirus type 4-vectored SARS-CoV-2 vaccines induce durable and efficacious responses in preclinical testing.

Kim Breanna, Roenicke Rachel, Roeder Peyton M, Steinberg Isabel, Patamawenu Andy, Harrison Mitra, Veer Freya Van't, Koory Emma, Xie Jane, Shofner Tulley, Matsuda Kenta, Wettstein Eleanor, Ober Ellison, Cooney Ceanna, Kim Tae, Webber Jonathan D, Meeks Tyler, Park Chung, Burdette Tracey, Georgia Shalamar, Readler James M, Vostal Alexander C, Hostal Anna, Cohen Jeffrey I, Gagne Matthew, Ziff Zohar, Richard Ketan, Burnett Matthew R, Maule Erin, Callier Viviane, Liang Jason, Kovacikova Gabriela, Souter Scarlett C, Weiner Joshua A, Douek Daniel, Ackerman Margaret E, Wright Peter F, Johnson Reed F, Connors Mark

СтатьяПеревод пока не подготовлен

Аннотация

The portfolio of next-generation COVID-19 vaccines would benefit from candidates that induce durable systemic and mucosal immune responses that would lessen person-to-person transmission. We constructed an intranasal (IN) replication-competent adenovirus type 4 recombinant platform to express SARS-CoV-2 spike variants (Ad4-S) and assessed immunogenicity and efficacy in the Syrian hamster model. Although both IN Ad4-S and intramuscular (IM) vaccines (Ad26.CoV2.S and mRNA-1273) induced serum binding antibodies, only Ad4-S induced a robust nasal mucosal response. IN Ad4-S vaccination induced serum neutralizing titers equivalent to or greater than IM vaccination but more durable up to 6 months. Upon challenge, IN immunization also resulted in less weight loss, greater breadth and durability of restriction of viral replication, and less lung pathology than IM immunization up to 268 days after immunization. These data support the potential of the IN Ad4 vaccine platform to reduce the transmission of SARS-CoV-2 and other respiratory viruses with pandemic potential.

Для цитирования: Kim Breanna, Roenicke Rachel, Roeder Peyton M, Steinberg Isabel, Patamawenu Andy, Harrison Mitra, Veer Freya Van't, Koory Emma, Xie Jane, Shofner Tulley, Matsuda Kenta, Wettstein Eleanor, Ober Ellison, Cooney Ceanna, Kim Tae, Webber Jonathan D, Meeks Tyler, Park Chung, Burdette Tracey, Georgia Shalamar, Readler James M, Vostal Alexander C, Hostal Anna, Cohen Jeffrey I, Gagne Matthew, Ziff Zohar, Richard Ketan, Burnett Matthew R, Maule Erin, Callier Viviane, Liang Jason, Kovacikova Gabriela, Souter Scarlett C, Weiner Joshua A, Douek Daniel, Ackerman Margaret E, Wright Peter F, Johnson Reed F, Connors Mark. Intranasal replicating adenovirus type 4-vectored SARS-CoV-2 vaccines induce durable and efficacious responses in preclinical testing.. iScience. 2026. DOI: 10.1016/j.isci.2026.115433.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.